TissueGene Initiates Phase I Clinical Trial With TG-C

TissueGene, Inc., a
privately- held biopharmaceutical company advancing a pipeline of promising
regenerative medicine therapeutics, announced today the acceptance of the
Company's Investigational New Drug application (IND), and for the
initiation of its Phase I clinical trial evaluating a single dose of TG-C
for the treatment of degenerative joint diseases. This clinical trial is
designed to assess the safety of TG-C in patients who have opted for total
knee arthroplasty.


TissueGene has developed TG-C to regenerate cartilage in patients
suffering from degenerative arthritis and more specifically for indications
such as osteoarthritis of the knee. As an alternative to other methods of
cartilage repair, TG-C will involve minimally invasive injections versus a
surgical approach. Other techniques currently involve multiple and often
invasive surgical procedures and have mixed results.


"We are pleased with the approval to start our Phase I program with
TG-C and feel that our drug candidate has the potential to be not
first-in-class, but also best-in-class," stated Dr. K.H. Lee, President,
founder and Chief Executive Officer of TissueGene.


About TissueGene:


TissueGene, Inc. is a privately-held biopharmaceutical company
developing a pipeline of promising regenerative medicine therapeutics in
the field of cell-mediated therapy, and has several related products in
development for the treatment of degenerative diseases. TissueGene is
focused on harnessing the power of well known, safe and effective growth
factors combined with the dynamic regenerative capacity of mammalian cells
to develop state of the art therapeutics.


For additional information on the company please visit
tissuegene.


TissueGene, Inc.

tissuegene